Cargando…

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies

Population pharmacokinetic (PK) and exposure‐safety analyses of alisertib were performed in children enrolled in 2 clinical trials: NCT02444884 and NCT01154816. NCT02444884 was a dose‐finding study in children with relapsed/refractory solid malignancies (phase 1) or neuroblastomas (phase 2). Patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xiaofei, Mould, Diane R., Yuan, Ying, Fox, Elizabeth, Greengard, Emily, Faller, Douglas V., Venkatakrishnan, Karthik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Pediatric Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274904/ https://www.ncbi.nlm.nih.gov/pubmed/34435684 http://dx.doi.org/10.1002/jcph.1958

Ejemplares similares

Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens
por: Suri, Ajit, et al.
Publicado: (2020)

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies
por: Faessel, Hélène M., et al.
Publicado: (2019)

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model‐Based Support for Body Surface Area‐Based Dosing Over the 2‐ to 16‐Year Age Range
por: Hanley, Michael J., et al.
Publicado: (2017)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
por: Falchook, Gerald S., et al.
Publicado: (2015)

Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
por: Suri, Ajit, et al.
Publicado: (2018)

Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients
por: Schmitz, Michael L., et al.
Publicado: (2020)

Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model
por: Völler, Swantje, et al.
Publicado: (2019)

Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study
por: Suri, Ajit, et al.
Publicado: (2019)

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
por: Gay, Carl M., et al.
Publicado: (2020)

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours
por: Faessel, Hélène, et al.
Publicado: (2019)

Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism
por: Damle, Bharat, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma
por: Takechi, Tomoki, et al.
Publicado: (2018)

Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship
por: Song, Zaiwei, et al.
Publicado: (2022)

Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass
por: Mian, P., et al.
Publicado: (2019)

Guaifenesin Pharmacokinetics Following Single‐Dose Oral Administration in Children Aged 2 to 17 Years
por: Thompson, Gary A., et al.
Publicado: (2016)

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2020)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer
por: Hirabatake, Masaki, et al.
Publicado: (2022)

Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma
por: Yang, Fen, et al.
Publicado: (2018)

Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults
por: Hanan, Nathan John, et al.
Publicado: (2019)

Combining selinexor with alisertib to target the p53 pathway in neuroblastoma
por: Nguyen, Rosa, et al.
Publicado: (2022)

Henoch-Schönlein Purpura Presenting in Association With Neuroblastoma: A Case Report
por: Alfath, Zineb, et al.
Publicado: (2020)

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
por: Chen, Justin A., et al.
Publicado: (2022)

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
por: O’Connor, Owen A., et al.
Publicado: (2019)

Randomized Population Pharmacokinetic Analysis and Safety of Intravenous Acetaminophen for Acute Postoperative Pain in Neonates and Infants
por: Hammer, Gregory B., et al.
Publicado: (2019)

First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model
por: Chen, Jinliang, et al.
Publicado: (2022)

Safety of Therapeutic Apheresis in Children and Adolescents
por: Taylan, Christina, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
por: Berg, Jolene K., et al.
Publicado: (2018)

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015)

Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV
por: von Kleist, Max, et al.
Publicado: (2020)

Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions
por: Muchohi, Simon N, et al.
Publicado: (2008)

Insights into the pharmacodynamics and pharmacokinetics of meldonium after exposure to acute high altitude
por: Liu, Fengying, et al.
Publicado: (2023)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
por: Monteith, David, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5ect1h94t87opav667kev9ccu0